title: Interferon-alpha counteracts the angiogenic switch and reduces tumor cell proliferation in a spontaneous model of prostatic cancer.
abstract: Interferon (IFN)-alpha is a cytokine with marked therapeutic activity in transplantable tumor models, that is in part due to angiogenesis inhibition. Aim of this study was to investigate the effects of IFN-alpha during the early phases of tumor development in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model. To provide sustained IFN-alpha production, TRAMP mice were injected intraperitoneally with lentiviral vectors. IFN-alpha administration resulted in rapid and protracted upregulation of IFN-alpha-regulated genes associated with antiangiogenic and antiproliferative functions in the prostate of TRAMP mice, including guanylate-binding protein 1 (GBP-1), IFI204 and CXCL10-11. These transcriptional changes were accompanied by effects on the tumor vasculature, including significant reduction of intraductal microvessel density and increased pericyte coverage, and marked reduction of tumor cell proliferation, without induction of tumor necrosis. Intriguingly, GBP-1 and myxovirus resistance A, two IFN-regulated proteins, were found expressed in approximately 40% of human prostate cancer samples analyzed, suggesting expression of endogenous IFN-alpha. Overall, these findings demonstrate that IFN-alpha is able to counteract the angiogenic switch and impairs tumor cell proliferation in preinvasive lesions. Since the angiogenic switch also marks progression of human prostatic cancer, these results highlight the potential of angiogenesis inhibitors for the development of chemoprevention strategies in high-risk individuals.
authors.affiliation: Oncology Section, Department of Oncology and Surgical Sciences, University of Padova, Padova I-35128, Italy.
authors.forename: Luca
authors.initials: L
authors.lastname: Persano
authors.forename: Lidia
authors.initials: L
authors.lastname: Moserle
authors.forename: Giovanni
authors.initials: G
authors.lastname: Esposito
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Bronte
authors.forename: Vito
authors.initials: V
authors.lastname: Barbieri
authors.forename: Massimo
authors.initials: M
authors.lastname: Iafrate
authors.forename: Marina P
authors.initials: MP
authors.lastname: Gardiman
authors.forename: Patrizia
authors.initials: P
authors.lastname: Larghero
authors.forename: Ulrich
authors.initials: U
authors.lastname: Pfeffer
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Naschberger
authors.forename: Michael
authors.initials: M
authors.lastname: Stürzl
authors.forename: Stefano
authors.initials: S
authors.lastname: Indraccolo
authors.forename: Alberto
authors.initials: A
authors.lastname: Amadori
mesh_terms: D002455:Cell Division; D019204:GTP-Binding Proteins / Q000235:genetics; D006801:Humans; D016898:Interferon-alpha / Q000502:physiology*; D008297:Male; D064547:Myxovirus Resistance Proteins; D009389:Neovascularization, Pathologic / Q000235:genetics / Q000503:physiopathology*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology* / Q000601:surgery; D012333:RNA, Messenger / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014158:Transcription, Genetic
chemical_list: C490287:GBP1 protein, human; D016898:Interferon-alpha; D064547:Myxovirus Resistance Proteins; D012333:RNA, Messenger; D019204:GTP-Binding Proteins